Consensus Hanall Biopharma Co., Ltd.

Equities

A009420

KR7009420001

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
37,600 ^KRW	+1.76%		+12.07%	-15.12%

May. 03	HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease	CI
Mar. 06	Hanall Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on Hanall Biopharma Co., Ltd.

Price target over the last 5 years

History of analyst recommendation changes

3aef595212170b15958adc.9TZSgVE41XsJXqXNTP_nTu_oTzNcTLjeGx4Wt88P5Z0.pFACxTxLnAFEE_ejesmMDYeGNwYQfZWNV0pOwa5r1fKmZgrGHwmwA3sZzg~820b2bd5ea6aaef59cfcb0bb95ef767f

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

37,600 KRW

Average target price

43,600 KRW

Spread / Average Target

+15.96%

High Price Target

46,000 KRW

Spread / Highest target

+22.34%

Low Price Target

39,000 KRW

Spread / Lowest Target

+3.72%

Consensus detail

Consensus revision (last 18 months)

Ratings for Hanall Biopharma Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar